Cholera Incidence and Mortality in Sub-Saharan African Sites during Multi-country Surveillance
- PMID: 27186885
- PMCID: PMC4871502
- DOI: 10.1371/journal.pntd.0004679
Cholera Incidence and Mortality in Sub-Saharan African Sites during Multi-country Surveillance
Abstract
Background: Cholera burden in Africa remains unknown, often because of weak national surveillance systems. We analyzed data from the African Cholera Surveillance Network (www.africhol.org).
Methods/ principal findings: During June 2011-December 2013, we conducted enhanced surveillance in seven zones and four outbreak sites in Togo, the Democratic Republic of Congo (DRC), Guinea, Uganda, Mozambique and Cote d'Ivoire. All health facilities treating cholera cases were included. Cholera incidences were calculated using culture-confirmed cholera cases and culture-confirmed cholera cases corrected for lack of culture testing usually due to overwhelmed health systems and imperfect test sensitivity. Of 13,377 reported suspected cases, 34% occurred in Conakry, Guinea, 47% in Goma, DRC, and 19% in the remaining sites. From 0-40% of suspected cases were aged under five years and from 0.3-86% had rice water stools. Within surveillance zones, 0-37% of suspected cases had confirmed cholera compared to 27-38% during outbreaks. Annual confirmed incidence per 10,000 population was <0.5 in surveillance zones, except Goma where it was 4.6. Goma and Conakry had corrected incidences of 20.2 and 5.8 respectively, while the other zones a median of 0.3. During outbreaks, corrected incidence varied from 2.6 to 13.0. Case fatality ratios ranged from 0-10% (median, 1%) by country.
Conclusions/significance: Across different African epidemiological contexts, substantial variation occurred in cholera incidence, age distribution, clinical presentation, culture confirmation, and testing frequency. These results can help guide preventive activities, including vaccine use.
Conflict of interest statement
I have read the journal's Policy and the authors of this manuscript have declared that no competing interests exist. However AMP receives grant specific funding from Crucell, GSK, Merck, Novartis, Pfizer, and Sanofi Pasteur. Sanofi Pasteur is a manufacturer of cholera vaccine (through Shanta Biotechnics) but did not provide funding for the current project or other work conducted by the study team on cholera. This does not alter our adherence to all PLOS policies on sharing data and materials.
Figures
References
-
- Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis. 2007; 7: 521–530. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
